From: Correction to: Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option
Strategy Name
Cost
QALYs
Incremental cost-effectiveness ratio ($/QALY)
No vaccine
2379.945
17.71296
(−)
LLR vaccine
2507.851
22.65899
0
Rotarix vaccination
5982.187
24.31454
2105.66
Rotateq vaccination
5577.902
24.44506
1715.14